BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia

BACKGROUND: BCL2 protein inhibitor venetoclax (ABT-199) has been authorized by Food and Drug Administration for relapsed/refractory chronic lymphoid leukemia with 17p deletion. Although venetoclax/ABT-199 also caused cell death in acute myeloid leukemia (AML), whether it could be applied to clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jing-dong, Zhang, Ting-juan, Xu, Zi-jun, Gu, Yu, Ma, Ji-chun, Li, Xi-xi, Guo, Hong, Wen, Xiang-mei, Zhang, Wei, Yang, Lei, Liu, Xing-hui, Lin, Jiang, Qian, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599255/
https://www.ncbi.nlm.nih.gov/pubmed/31253168
http://dx.doi.org/10.1186/s13000-019-0841-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599255/
https://www.ncbi.nlm.nih.gov/pubmed/31253168
http://dx.doi.org/10.1186/s13000-019-0841-1

Ejemplares similares